Tevimbra Approved for Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemo

The FDA has approved tislelizumab-jsgr (Tevimbra, BeiGene), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) cancers in adults whose tumors express PD-L1 (programmed death ligand-1) (≥1).

The additional indication for first-line G/GEJ cancers is based on results from RATIONALE-305 (ClinicalTrials.gov. Identifier: NCT03777657), a randomized,